These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17498515)

  • 1. Drug treatment of the overweight patient.
    Bray GA; Ryan DH
    Gastroenterology; 2007 May; 132(6):2239-52. PubMed ID: 17498515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapeutic options for overweight adolescents.
    Dunican KC; Desilets AR; Montalbano JK
    Ann Pharmacother; 2007 Sep; 41(9):1445-55. PubMed ID: 17652127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R; Li SK; Lau DC
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
    Caterson ID; Finer N
    Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R
    Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of obesity.
    Sidhaye A; Cheskin LJ
    Adv Psychosom Med; 2006; 27():42-52. PubMed ID: 16418541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
    Block JP; Choudhry NK; Carpenter DP; Fischer MA; Brennan TA; Tong AY; Matlin OS; Shrank WH
    Obesity (Silver Spring); 2014 Mar; 22(3):943-9. PubMed ID: 23929685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.